1,309 WHO Grade 2 and 3 glioma patients from AACR GENIE v13.0 datasets were grouped based on IDH1 mutation status, and individual cases were aligned based on CNVs status of EGFR, CDKN2A, and PTEN, as well as mutation status of TP53 and ATRX (Fig. 4B,C). This evidence concerns the gene CDKN2A and central nervous system cancer.